Corticosteroids have been used in combination with chemotherapy for the treatment of metastatic castration-resistant prostate cancer (mCRPC) for more than three decades, particularly to treat pain, inflammation, and edema. More recently, they have been used in combination with hormonal agents. The importance of corticosteroids in mCRPC is due to their ability to manage adverse effects, reduce symptoms, and improve patients' quality of life. The appropriate selection of available options in mCRPC should be based on careful consideration of a patient's profile and comorbidities. This review provides an overview of the role of corticosteroids in treating mCRPC for the practicing urologist.
Urology. 2016 Feb 18 [Epub ahead of print]
Maria De Santis, Fred Saad